A phase 3 clinical trial of VY-AADC for Parkinson's disease
Latest Information Update: 15 Sep 2020
At a glance
- Drugs Ezaladcigene resoparvovec (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms RESTORE-2
- Sponsors Voyager Therapeutics
Most Recent Events
- 11 Sep 2020 According to a Neurocrine Biosciences media release, preparations are ongoing for this global registrational trial that will include clinical sites within and outside the U.S.
- 10 Aug 2020 event According to a Neurocrine Biosciences media release , it plan to initiate the RESTORE-2 Phase 3 global registrational clinical study of VY-AADC (NBIb-1817) in Parkinsons disease during the first half of 2021.
- 12 Jan 2020 According to a Neurocrine Biosciences media release, the company expects to initiate this trial in 2H 2020.